Below is a list of the most popular Monkeypox stocks. Another year, another disease. There’s a monkeypox outbreak. Thankfully, this disease has been around for decades and is well-documented. On another positive note, there aren’t any recorded deaths due to the illness. What did it do to the stock market?
Symptoms include large lymph nodes and lesions in multiple parts of the body. Recovery time is 2 to 3 weeks. The disease comes from Africa but has already spread to many European and North American countries.
Most countries don’t vaccinate for this disease, and we might not have any immunity. It’s a good thing we are prepared in case of another pandemic. Many companies have successful programs to deal with this type of disease.
Let’s explore which ones may come on top if the disease begins to affect our communities. As a bonus, we will also explore how companies that offered a COVID-19 vaccine have been doing since the pandemic began and whether they’re invested in a Monkeypox vaccine. What does this mean if you want to invest in Monkeypox stocks? Let’s keep reading.
Best Monkeypox Stocks 2026\
| Symbol | Name |
|---|---|
| BVNRY | Bavarian Nordic |
| EBS | Emergent Biosolutions |
| SIGA | SIGA Technologies |
Emergent Biosolutions (NYSE: EBS)
Emergent Biosolutions is a US company based in Maryland. It develops treatments for various diseases and infections, and medical devices. The stock gained momentum during the early COVID days thanks to manufacturing contracts for the AstraZeneca and J&J vaccines.
Unfortunately, the US Food and Drug Administration (FDA) uncovered that the ingredients were mixed between both vaccines. They may not be thorough, but they have the infrastructure to produce vaccines in large doses.
The company is also well-positioned in case of an eventual outbreak. However, it has not happened. It has the only one-dose smallpox vaccine allowed by the FDA. Furthermore, Emergent acquired the rights to another smallpox cure from fellow competitor Chimerix (NASDAQ: CMRX).
This puts Emergent in a good position to deal with an eventual crisis. So, if you want to invest in Monkeypox stocks, keep this in mind.
SIGA Technologies (NASDAQ: SIGA)
SIGA is another US company based in New York with an FDA-approved smallpox medication. One major difference is its product, Tpoxx, which has already been approved in Europe to treat smallpox and Monkeypox. SIGA also got its intravenous version of the medication approved by the FDA earlier this month.
The number of cases had been rising, and the US and the EU had already requested SIGA to produce and distribute a small number of doses in case of an outbreak. Since then, the stock has risen.
This was short-lived, as no outbreak occurred. So keep that in mind when you invest in Monkeypox stocks.
Bavarian Nordic (OTCMKTS: BVNRY)
Bavarian Nordic is a Danish biotech company. It focused on the development, manufacturing, and commercialization of various vaccines. The company has an approved product in Europe, Canada, and the US. It is efficient against Monkeypox.
The company received an order from a mysterious European country to combat the spread of the disease. Many countries are taking preventive measures to combat another potential epidemic.
The markets reacted positively to this news for the company. The stock rose, but it might be short-lived once again unless a real epidemic occurs.
COVID Stocks
This section will revisit many COVID-19 pharmaceutical stocks that benefited from the pandemic.
Do they have a vaccine ready against Monkeypox, and how has their stock performed since the vaccine rollout? Let’s find out.
What will this mean if you want to invest in Monkeypox stocks?
Moderna (NASDAQ: MRNA)
Since the beginning of the pandemic, Moderna’s stock has gained more than 600%. Pharmaceutical and biotech companies can produce hundreds of millions of COVID-19 doses yearly.
Many governments around the world have stopped caring about the pandemic. Life goes on, and vaccination is no longer mandatory.
Life is back to normal, like COVID-19 never happened. Monkeypox was nothing but hype for a couple of weeks. Hopefully, if you invested in Monkeypox stocks, you got some return from them.
Since the disease has been around for decades, releasing something in a few weeks shouldn’t be too difficult. Will governments turn to this giant once again, or will smaller competitors with existing proven products come on top? Only time will tell.
Pfizer (NYSE: PFE)
Unlike Moderna, Pfizer has seen much more modest growth since the pandemic’s beginning, less than 50%. One reason is a much smaller production capacity than Moderna, less than half.
Another reason is that it was deemed less efficient. I won’t get into the specifics. As for a Monkeypox vaccine, Pfizer doesn’t have an existing one, and there isn’t any news about one in the works.
Instead, the company concentrated on its COVID-19 vaccine for toddlers and babies and ramped up production for the next wave. The company is concentrating on its bread and butter. However, nothing happened.
Johnson & Johnson (NYSE: JNJ)
We conclude this section with Johnson & Johnson. The 19th-century pharma company shocked many with its one-dose vaccine that wasn’t as effective as its counterparts.
In response, the markets didn’t respond as positively. The company has been around for decades and has diverse products in many health categories. Its COVID-19 vaccine is only a part of its success. As a result, many analysts are quite bullish on JNJ.
As for a Monkeypox cure, JNJ doesn’t have any at the moment or in the works. However, they are not succumbing to the hype until a need arises.
VIRS ETF Performance (2026 YTD)
| Year | Performance | 2026 (YTD) | -2.7% |
|---|---|
| 2025 | +14.2% |
| 2024 | +9.5% |
| 2023 | -6.8% |
| 2022 | -12.4% |
Risks of Investing in Monkeypox Stocks
Before investing in any of these stocks, it’s important to establish that although Monkeypox is contagious, it is less deadly than other diseases. It’s not a pleasant experience, but the symptoms will be gone after 2-3 weeks.
Most countries decided not to vaccinate their people for decades because the disease is mostly found in Africa. However, if countries worldwide decide to push a vaccine, many companies will benefit since it can be produced easily.
Until there is a concrete decision or action plan, the stock price of any relevant company will continue to be very volatile. Unless diverse products are in the pipeline, it isn’t worth a significant investment. A Monkeypox YOLO investment isn’t suggested. Invest with caution.
Final Thoughts: Monkeypox Stocks
To conclude, there isn’t a real urgency to combat Monkeypox. Cases are rising very slowly, but it isn’t a deadly disease. A vaccine plan isn’t in the works unless there is a major development.
Some smaller pharmaceutical and biotech companies have an existing product, but major players concentrate on more useful products. So, for now, Monkeypox stocks can be a good day trading option, but it isn’t a long-term play.
COVID stocks may last a few more quarters. It all depends on when governments stop caring and live with it. Pharma stocks are always tricky since demand isn’t constant for all products. Some periods are better than others, depending on the demand. Please do not trade any of the securities on this Monkeypox stocks list unless you know how to trade.
Frequently Asked Questions
Three companies are on tap for any potential Monkeypox outbreak: Quest Diagnostics, Bavarian Nordic, and Siga Technologies.
Monkeypox comes from Africa. Bavarian Nordic is the company that has developed a Monkeypox vaccine. However, the sickness isn't deadly.
Monkeypox peaked in August 2022. It hasn't done much of anything since.
